U.S. Machinery Stock News

COPT Defense Properties recently executed build-to-suit leases with a Fortune 100 company in San Antonio and the University of Maryland’s ARLIS in College Park, committing about US$153 million of capital to high-security and research-focused developments after completing 557,000 square feet of vacancy leasing in 2025. These projects deepen COPT Defense’s presence in mission-critical Defense/IT and university-affiliated research hubs, underscoring strong tenant demand for secure, specialized...

Earlier this month, DoubleVerify launched DV Authentic Streaming TV at CES 2026, an AI-powered solution aimed at improving transparency, media quality, and ad performance for connected and streaming TV campaigns by unifying content discovery, reporting, analytics, and optimization in a single workflow. A distinctive feature is its use of granular program-level and app-level signals, such as genre, maturity ratings, viewer scores, and attention insights, to give advertisers more accountable...

On January 1, 2026, iQIYI announced that iQIYI LAND, its first global offline entertainment park, would open in Yangzhou on February 8, 2026, featuring seven immersive zones built around its Chinese film and TV IP, with ticket presales starting January 16. This move extends iQIYI’s content ecosystem into offline, tech-enabled themed experiences, tapping into China’s growing theme park sector while reinforcing the value of its existing IP portfolio. We’ll now examine how launching iQIYI LAND...

Insider buying and dividend change put Dorchester Minerals (DMLP) in focus Recent insider buying by CEO Bradley J. Ehrman, alongside a higher quarterly dividend, has pushed Dorchester Minerals (DMLP) onto many investors’ watchlists as they reassess the partnership’s income profile and management alignment. See our latest analysis for Dorchester Minerals. At a share price of US$23.19, Dorchester Minerals has seen a mixed pattern recently, with a 1 day share price return of 1.27% and a 30 day...

Maze Therapeutics (MAZE) has drawn investor interest after recent trading performance, with the stock closing at US$40.32. You might be asking how that price lines up with the company’s current fundamentals. See our latest analysis for Maze Therapeutics. The recent 46.99% 3 month share price return suggests momentum has been building around Maze Therapeutics, even as investors weigh its early stage pipeline against current financial results. If Maze has caught your attention, this could be a...

In early January 2026, Verint Systems announced it had won two TrustRadius 2026 Buyer’s Choice awards, with top ratings in the Contact Center category based on customer reviews. The awards highlight customer trust in Verint’s AI and automation-powered CX Automation platform, underlining its ability to deliver measurable business outcomes at scale. We’ll now examine how this fresh customer-driven recognition of Verint’s AI-powered CX Automation platform may influence the company’s broader...

In the past week, Goldman Sachs downgraded HealthEquity (NASDAQ: HQY) from Neutral to Sell, sparking a reassessment of the company’s outlook among Wall Street analysts. This downgrade stands in contrast to other firms that have recently reiterated or raised positive ratings, underscoring growing debate over HealthEquity’s near-term growth drivers and business momentum. We’ll now examine how Goldman Sachs’ bearish turn and the emerging split in analyst opinion may reshape HealthEquity’s...

RXO (RXO) stock has been in focus after the company reported stronger quarterly revenue and a much smaller GAAP loss than a year ago, along with insider share purchases that drew fresh investor attention. See our latest analysis for RXO. The stronger quarter and insider buying have arrived after a mixed stretch for investors, with a 7 day share price return of 14.88% and a 1 year total shareholder return decline of 39.23%, suggesting recent momentum is improving from a weaker longer term...

Why Old Second Bancorp is back on investors’ radar Old Second Bancorp (OSBC) is attracting attention after several years of strong net interest income growth, linked to its high-yielding loan book and 4.8% net interest margin, which are supporting market share gains. See our latest analysis for Old Second Bancorp. At a share price of $19.78, Old Second Bancorp has seen a 16.01% 90 day share price return, while its 1 year total shareholder return of 16.18% and 5 year total shareholder return...

What recent performance says about Phathom Pharmaceuticals Without a single clear news catalyst, Phathom Pharmaceuticals (PHAT) has still drawn attention after a recent month of modest gains, a stronger move over the past 3 months, and a sharply positive 1 year total return. Those returns sit against a value score of 4 and a share price of about $15.02 at the last close. This has prompted some investors to compare that recent performance with the company’s current fundamentals. See our latest...

Earlier this week, Needham analyst Tom Nikic upgraded Steven Madden from Hold to Buy, citing the company’s positioning to benefit from evolving fashion trends and the integration of recently acquired Kurt Geiger. The upgrade reflects growing analyst confidence that Kurt Geiger could meaningfully enhance Steven Madden’s sales mix and profitability profile over the next few years. We’ll now examine how expectations for margin improvement from the Kurt Geiger acquisition may influence Steven...

Recent performance snapshot for Hanover Insurance Group Hanover Insurance Group (THG) has drawn investor attention after a period where the share price showed a 2% decline over the past week and a 6.3% decline over the past month. Over the past 3 months, the stock shows a 2.5% decline, while the year to date return is down 3.3%. This sits alongside a 1 year total return of 20.2% and a 5 year total return of 63.1%. See our latest analysis for Hanover Insurance Group. Recent share price...

Oculis Holding AG recently announced that the U.S. FDA granted Breakthrough Therapy Designation to its neuroprotective candidate Privosegtor for optic neuritis, supported by positive Phase 2 ACUITY trial data and initiation of the PIONEER registrational program in multiple optic neuropathies. This milestone, alongside the late-stage OCS-01 eye drop program for diabetic macular edema, positions Oculis as an emerging player in high unmet-need neuro-ophthalmic and retinal diseases with...

Falling interest rates and easier lending standards have put Enova International (ENVA) back in focus for investors, as its data driven fintech lending model and shareholder returns come under renewed scrutiny. See our latest analysis for Enova International. At a latest share price of $161.6, Enova’s 30 day share price return of 14.29% and 90 day share price return of 55.37% sit alongside a 1 year total shareholder return of 70.03% and 5 year total shareholder return above 5x. This suggests...

In early January 2026, Appian said it will press ahead with its trade secret lawsuit against Pegasystems after the Virginia Supreme Court sent the case back for retrial and rejected Pegasystems’ bid to have it thrown out, with the court’s opinion describing how Pegasystems allegedly hired a “spy” to obtain Appian information. The continued legal battle, including unresolved trade secret claims and an unchallenged finding under the Virginia Computer Crimes Act, keeps legal risk and potential...

What Perdoceo’s New Buyback Means for Investors Perdoceo Education (PRDO) has put a fresh US$100 million share repurchase program in place, replacing its earlier authorization and running through June 30, 2027, while reaffirming its 2026 adjusted operating income outlook. This combination of a new buyback and unchanged guidance gives investors a concrete update on how management is thinking about capital allocation, earnings quality and the current share price, all using information the...

In December 2025, NRSInsights reported that same-store sales on the National Retail Solutions point-of-sale platform increased 4.5% year over year, while the average price paid for the top 500 items rose 2.3%. This combination of higher volumes and prices points to resilient demand at independent retailers using IDT’s NRS platform, underlining the importance of its data-driven retail ecosystem. Next, we’ll examine how this December same-store sales growth could influence IDT’s existing...

In early January 2026, Rapport Therapeutics announced that the FDA had cleared RAP-219 to enter Phase 3 registrational trials for focal onset seizures and confirmed broader pipeline progress, including bipolar mania, long-acting injectables, and a lifted clinical hold on its diabetic peripheral neuropathic pain trial. This combination of an advanced late-stage epilepsy program and a broadened neurology and pain portfolio highlights Rapport’s effort to build a multi-indication franchise...

This article is for readers wondering whether Star Bulk Carriers still offers value at today’s price or whether most of the opportunity is already reflected in the share price, and is aimed at helping you frame that question clearly. The stock closed at US$19.64, with returns of 1.4% over 7 days, 0.9% over 30 days, 1.4% year to date and 31.0% over the past year, plus 16.3% over 3 years and 199.1% over 5 years. These figures can shape how investors think about both upside and risk...

Enliven Therapeutics (ELVN) shares moved after the company released encouraging initial Phase 1b ENABLE data for ELVN-001 in heavily pretreated chronic myeloid leukemia patients who are relapsed, refractory, or intolerant to existing tyrosine kinase inhibitors. See our latest analysis for Enliven Therapeutics. The latest ENABLE readout arrived alongside a board refresh, with industry veteran Scott Garland joining as a director. The stock has been highly reactive. Enliven Therapeutics has seen...

Kadant recently benefited from a sector-wide rally in industrial names after President Trump called for a proposed US$1.50 trillion defense budget for 2027, prompting investors to reassess companies connected to industrial and defense supply chains. The market’s reaction suggests that while the defense-spending proposal does not fundamentally alter Kadant’s core equipment and aftermarket businesses, it has reinforced investor attention on its exposure to broader industrial investment...

In recent days, Zoom Communications has opened nominations for its Zoom Solopreneur 50 List, while also drawing increased attention from analysts following upward revisions to earnings estimates and a Zacks Rank #1 (Strong Buy) rating based on consistent earnings and revenue outperformance. This combination of an AI-focused small-business grant initiative and improving earnings expectations highlights how Zoom is positioning itself at the intersection of artificial intelligence and...

Cabot Corporation recently signed a multi-year supply agreement with PowerCo SE, a Volkswagen Group battery subsidiary, to provide advanced conductive carbons and dispersions for lithium-ion EV battery electrodes across Europe. This partnership deepens Cabot’s role in the EV battery supply chain, highlighting its specialized materials as an enabler of higher performance next-generation electric vehicles and energy storage systems. We’ll now examine how this PowerCo SE agreement, centered on...

Recent commentary around Copart (CPRT) has focused on rising competition from IAA, backed by RB Global, and the effect on market share, growth momentum, and investor confidence in the company’s premium valuation. See our latest analysis for Copart. Copart’s share price has been choppy, with a 2.02% 1 day share price return and 5.45% 7 day share price return, but a 9.23% 90 day share price decline and 28.41% 1 year total shareholder return decline. These figures suggest momentum has been...